Oncology

The first-and-only fully human monoclonal anti-epidermal growth factor receptor antibody for the treatment of wild-type RAS metastatic colorectal cancer was recently approved by the US Food and Drug...

The FDA approved new options for non-small cell lung cancer, von Willebrand disease, and to treat overdoses of certain chemotherapies.

The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.

The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.